2022 Update from LPBI Group
Author & Curator: Aviva Lev-Ari, PhD, RN
Picture on 2/6/2022
BIO
UPDATED on 4/25/2022
We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022
UPDATED on 3/10/2022
LPBI Group https://pharmaceuticalintelligence.com/
offers the opportunity to play a pivotal role in Founder’s quest for Transfer of Ownership over our Portfolio of 14 IP Asset Classes:
https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/
The vast IP Portfolio of LPBI Group requires an investor as a new owner and a new operating team to celebrate, articulate and position LPBI Group in front of potential 3rd Party suiters as potential acquirers of the Portfolio of our IP Assets in an advantageous manner to benefit LPBI Group. Since inception, 4/2012, we are self financed and debt free.
- The unique strength of LPBI Group is in the following business dimensions:
- Market penetration of Existing pharmaceutical and Medical CONTENTS:
- +2.1 Million Journal Article Views of +6,100 scientific articles
- +147,000 book page downloads, 18 volumes in Medicine
- Curation methodology and publishing engine
- Composition of Methods unrelated to our Curations as products or our process for creation of curations.
- Domain Knowledge Experts.
- Transition from e-Scientific Publisher to Software driven business for 2.0 LPBI Group, 2021-2025, a pipeline of four missions: A,B,C,D:
(A) Text Analysis with Artificial Intelligence (NLP, ML, DL) of our own 18 books in Medicine
https://lnkd.in/ekWGNqA
(B) Blockchain IT for content monetization using NFT Auctions
https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/
- B2C (digital content in Life Sciences & Medicine using Ontology searches) and
- B2B (auction of drug molecules designed with software by LPBI Group team and by 3rd parties)
(C) New Genre of Scientific Books: Same 18 Books republish with new content (PART B: NLP) and in new Media (Audio) and in Spanish
- PART A: Spanish Audio, Bi-Lingual Text,
- PART B: NLP results and interpretation of the Text Analysis with Machine Learning,
- PART C: Editorials Audio
(D) Drug Design with Synthetic Biology Software PRosettaC targeting Galectins. Products will be auctioned on the Blockchain IT Transactions network
https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
- The Methodology of Curation is the tool in use for content creation of the Clinical Interpretations of Scientific Findings reported in experiments and clinical trials in peer reviewed journal articles
- Domain knowledge experts:
1.0 LPBI, 2012-2020 – Experts, Authors, Writer (EAW) and Editors
2.0 LPBI, 2021-2025 – EAW engaged in the interpretation of the Text Analysis with NLP visualization results
- LPBI Group’s Composition of Methods developed by 1.0 LPBI, 2012-2020 [not related to Curation] includes the following assets:
(a) Platforms of Publishing Scientific Content
(b) Portals,
(c) Workflows,
(d) Multiple Template Systems developed for the production of e-Proceedings and Tweet collections
(e) Schemas and Styles for e-Books eTOCs
(f) Library of 280 Podcasts
(g) Gallery of +6,200 Biological Images
(h) Spanish content
Strategies to be considered:
- Keeping LPBI Group’s Portfolio whole, versus
- By Asset Class dividing the Portfolio into 14 assets
WebMD established in 1995-97 as 1st Medical Website. It had 6 businesses going on in parallel. KKR, the acquirer in 7/2017, kept them all together due to synergies derived from cross asset access under one owner https://pharmaceuticalintelligence.com/2017/07/25/ma-of-online-health-publisher-webmd-health-corporation-by-kkr-co-dynamics-in-health-care-media-web-health-and-health-information-markets/
We have done substantial work on documenting what we produced. We are top Thinkers creating Record of Innovations:
- See Update on 2/26/2022 https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/aviva-lev-ari-phd-rn-founder-lpbi-group-1-0-2-0/
We seek investor’s view of a New Owner and New management for LPBI Group’s business strategy for prospecting for an acquirer of LPBI Group’s Portfolio of IP Assets.
2022 Update from LPBI Group
This article has five parts:
Part 1: Web Site Statistics
Part 2: 2.0 LPBI Group’s Four Missions: The Pipelines for 2021-2025
Part 3: Portfolio of IP Assets
Part 4: Certificates – One Year Academic Internships in six Disciplines
Part 5: Top 14 Articles by Views, All Time
Part 1: Web Site Statistics
Journal Statistics on April 20, 2022 |
|
Total # of Article Views |
2,114,157 |
Total # of Scientific Comments |
7,932 |
Total # of Categories in Journal’s Ontology |
743 |
Total # of Tags |
10,653 |
Total # of Scientific Articles: Curations and Scientific Reports |
6,131 |
2/1/2021 – 2/3/2022 One year Increase in % |
|
Total # of Views |
8.59 |
Total # of Comments |
5.41 |
Total # of Categories |
2.06 |
Total # of Tags |
2.03 |
Total # of Posts |
5.41 |
Top Authors Number of Journal Articles as a Single Author on 3/31/2022 |
Total Views by Author on 3/31/2022 |
Aviva Lev-Ari, PhD, RN
(N = 3,586) |
509,231 |
Larry H Bernstein, MD, FCAP
(N = 1,597) |
374,026 |
Stephen J Williams, PhD
(N = 354) |
72,783 |
Tilda Barliya, PhD
(N = 52) |
70,124 |
Sudipta Saha, PhD
(N = 127) |
39,166 |
Dror Nir, PhD
(N = 61) |
38,336 |
Demet Sag, PhD, CRA, GCP
(N = 112) |
20,074 |
Ritu Saxena, PhD
(N = 39) |
17,370 |
Gail S Thornton, PhD(c)
(N = 44) |
18,312 |
Irina Robu, PhD
(N = 179) |
10,292 |
Progression of Views by Author By Year – New Graph Updated 2/3/2021

Line Graph Depicting Top Authors Progression by Views Ending 2021-07-01
Date of Production: 2021-07-01
Part 2: Four Missions as 2021 – 2025 Pipelines
2.0 LPBI Missions
Four missions as LPBI’s exposition of the pipelines for
2021 -2025
Mission #1: NLP – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Statistical NLP and Deep Learning by Machine Learning using Wolfram Language for Biological Sciences
Mission #2: Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph Databases – Content monetization infrastructure B2B and B2C.
Scenario from the End User Perspective
- Interested parties posing queries to the system (B2C)
- System responds by triggering a Recommendation Engine Response (RER) that will fetch: top articles by views
- If the article was published in a book THEN the selected Article in the context of all articles in same chapter in the book it was featured will form the article collection for NLP performance.
- If article not in a book then in the context of other articles in same categories of research, ones selected by the recommendation engine and ranked by views.
- Biological images in these articles will be displayed
- NLP results in visual graphics will be displayed
- Major Data Science procedures in the back-end are using graph databases for on the Fly generation of NLP results not performed before, thus, not stored in the knowledge graph databases
- Domain Knowledge Expert interpretation of the graphics available for selection in several Foreign languages presented in the front-end.
- System invokes Blockchain features embedded per LPBI specifications into the API layer(s) of the Blockchain Transactions Network for its cardinal technology features: i.e.,
- Permissions
- Immutable LEDGER
- Smart Contracts
- Cyber security of IP assets in blocks
Full feature operations of the Blockchain platform will enable
- B2C – Digital Store on a Healthcare Digital Marketplace
- B2B – Installation at Big Pharma, Healthcare Insurers and CRO
https://pharmaceuticalintelligence.com/blockchain-transactions-network/
Mission #3: BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E
Mission #4: Synthetic Biology Software: Drug discovery Galectins
2.0 LPBI is a Very Unique Organization
Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and 2.0 LPBI, April 2012 to Present
LiSTEN TO THE PODCAST
https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/
Part 3: Portfolio of IP Assets
Data represent the views of LPBI Group’s Founder
An UPDATE is forthcoming



In the Voice of Dr. Williams
Please Refer to the following Excel file for a more detailed and larger view of the following tables






A stream of Ten INNOVATIONS in the Life of LPBI since inception in 2012 to 2021
- 4/2012 – LPBI was the Launcher of a novel Scientific Curation Methodology for scientific findings in published primary research in the Global e-Scientific Publishing industry https://pharmaceuticalintelligence.com/
- As late as 2016, no big publisher, not even one, i.e., Elsevier, John Wiley had curation-based publications: Journals, Books, e-Proceedings or Gallery of thousands of Biological Images as an IP asset class
- At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
- 6/2013 – LPBI was the Publisher of the 1st e-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
- 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine: each article in each volume is a curation-based publication.
- On Amazon.com on 7/2021 – LPBI’s e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads. The record is the equivalent of 64 books at an average of 2,000 pages a volume !!!! LPBI smallest book is 1,000 pages and its biggest is +3,700 pages
- LPBI launched its Natural Language Processing (NLP) Practice in 1/2020 as Mission #1. NLP is one method of Machine Learning (ML). ML is a family of methods in Artificial Intelligence (AI) which is a field in the Computer Science Academic discipline since the early 60s.
In 4/2021 Linguamatics/IQVIA performed NLP on LPBI’s 33 articles and 20 Biological Images. RESULTS: +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:
- Gene-Disease
- Gene-Drug
- Disease-Drug
These results were jointly presented to a Healthcare Insurer, SLC, UT on 7/13/2021, forthcoming meeting in 9/2021.
- LPBI and BurstIQ are architecting NOW the first Natural Language Processing – Blockchain Information Technology infrastructure in existence, This statement is TRUE.
- Updated on 7/28/2021: Fluree
Flur.ee, the Web3 Data Platform Open source semantic graph database & LeadSemantics.com presented their solution for NLP and Blockchain on 7/28/2021. Erich G. was lured as Chief architect for LPBI’s Mission #2: NLP & Blockchain
- Linguamatics, the leader in NLP did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER
IMAGE SOURCE: BurstIQ image for LPBI
- On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology Software for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, President and CSO, SBH Sciences, Inc., Natick, MA
- On 7/25/2021 – LPBI announced that it will have the NEWLY to be published BioMed e-Books As Mission #3:
A NEW Publishing GENRE of SCIENTIFIC BOOKS
o Bi-Lingual electronic Table Of Contents (eTOCs), English & Spanish with Montero Language Services, Madrid as the Translator of eighteen Books’ Cover Pages and the 18 books electronic Table of Contents.
o The Content promotion in the Spanish speaking Countries with GTO, Madrid as AD Agency.
o NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and in Audio: in Spanish and in other languages, forthcoming
o Original English Book – Only Editorials (Preface, Introductions, Summaries and Epilogue) because the Bi-Lingual part has the eTOCs of the e-Book
o This is a new genre and a new architecture of 18 MULTIMEDIA SCIENTIFIC e-Books with (a) NLP results of the Medical Text analysis with machine learning, (b) Expert Interpretation of the Visualization Results. Bi-Lingual Podcasts: (c) eTOCs and (d) Bi-Lingual Expert Interpretation in English and Spanish Text and audio Podcasts, and (e) Books’ Editorials in English Audio Podcast
Content promotion proposal by GTO, Madrid
IMAGE SOURCE: Rendition by GTO, Madrid of BurstIQ Image, above
- The Content Monetization effort includes the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products
Under development
- IP Valuation Model per IP asset class is needed to be compared with Master_Financials and to supplement it
- Pricing Model and Product Mix Models for the digital products to be generated by the process of Text Analysis with NLP are using a Product Price List already developed.
- The scenarios for a Probabilistic Product Mix for the B2B sector are work-in-progress. Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up with NLP Alliances. The Alliances are the Labor component and LPBI represent Materials (Content) as 25% of the contract price, on top of total, to be paid by the B2B customer as materials in use for the engagement.
- B2C Customers on Blockchain will use the Price List for all Digital Products of LPBI 1.0 and LPBI 2.0 – Pay per Use
Part 4: Certificates
One Year Academic Internships in six Disciplines
All INTERNSHIPS are TUITION FREE on a VOLUNTEER basis and involve a One Year Academic Training in the following areas.
LPBI Group will run SIX MAJOR INTERNSHIPS: Volunteer base
- We Offer esteemed Affiliation, Mentorship by Scientists
- NEW skills development in NLP, ML, AI applications to Medical Text and Drug Discovery
- References and Resume paragraph on accomplishments and goals during the INTERNSHIP
- Opportunity to contribute to Publications
- Explorations of opportunities in Life Sciences in the US
Detailed description to be found on each Internship page, below
- Medical Text Analysis (Deep Learning NLP)
- IS, IT, CS and Data Science Internship
- Blockchain Knowledge Graph Database Design with Interface to Wolfram NLP
- Finance Internship: Financial Modeling
- Synthetic Biology Software for Drug Design in Glycobiology Internship
- Journalism and Marketing Communications in Pharmaceutical Media
Part 5: Top 14 Articles by Views, All Time
Updated on 2/22/2022 by Aviva Lev-Ari, PhD, RN
NEW ARTICLE ARE IN THE TOP Fourteen on 3/31/2022
NEW #7: Pyrroloquinoline quinone (PQQ) – an unproven supplement – 7,759 Views, Author: Larry
NEW #9: Evolution of Myoglobin and Hemoglobin – 6,417 Views, Author: Larry
https://pharmaceuticalintelligence.com/2015/01/19/life-on-earth-is-traced-to-oxygen-binding/
GRAND TOTAL VIEWS for Top 14 articles on 3/31/2022 is
xx Views
ORIGINAL LIST OF TOP TWELVE ARTICLES on 3/31/2022
Article Name Live Link |
Views All Time UPDATED 0n 3/31/2022 |
Categories of Research | |
#1
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? |
17,476 |
Author:
LarryBiological Networks, CANCER BIOLOGY & Innovations in Cancer Therapy, Cell Biology, Disease Biology, Genome Biology, Imaging-based Cancer Patient Management, International Global Work in Pharmaceutical, Liver & Digestive Diseases Research, Metabolomics, Molecular Genetics & Pharmaceutical, Nutrition, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Population Health Management, Proteomics, Stem Cells for Regenerative Medicine, Technology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphate, ATP, Glycolysis, Hypoxia-inducible factors, Kreb, Lactate dehydrogenase, Mammalian target of rapamycin, Mitochondrion, Warburg Effect
#2
Recent comprehensive review on the role of ultrasound in breast cancer management
16,788
Author:
Dror NirBiomarkers & Medical Diagnostics, Health Economics and Outcomes Research, Healthcare costs and reimbursement, Imaging-based Cancer Patient Management, Medical Device Therapies for Altzheimer’s Disease, Medical Devices R&D Investment, Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound | Tagged breast biopsies, breast cancer, breast cancer management, breast cancer screening, breast cyst, breast lesions, breast ultrasound, mammography, MRI, Personalized medicine, PET, support breast cancer, tomosynthesis, yale university school, yale university school of medicine
#3
14,562
Author:
AvivaCoagulation Therapy and Internal Bleeding, Electrophysiology, FDA Regulatory Affairs, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease | Tagged Academic Medical Center, Amsterdam, Anticoagulant, Apixaban, Dabigatran, Direct thrombin inhibitor, Direct Xa inhibitor, Food and Drug Administration, New England Journal of Medicine, Non-steroidal anti-inflammatory drug, Northeastern University, PRADAXA, Prothrombin time, Rivaroxaban, VTE, Warfarin
#4
Paclitaxel vs Abraxane (albumin-bound paclitaxel)
16,600
Author:
TildaBioSimilars, CANCER BIOLOGY & Innovations in Cancer Therapy, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Nanotechnology for Drug Delivery, Pharmaceutical Analytics, Pharmaceutical R&D Investment, Regulated Clinical Trials: Design, Methods, Components and IRB related issues | Tagged Abraxane, albumin-bound paclitaxel, breast cancer, clinical studies, FREE paclitaxel, linear PK, non-linear PK, Paclitaxel, Pharmacokinetics, PK, side effects, Taxol
#5
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications
10,400
Author:
AvivaCoagulation Therapy and Internal Bleeding, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease, tagged Dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation
#6
10,064
Author:
AvivaMedical Devices R&D Investment, Nitric Oxide in Health and Disease, Technology Transfer: Biotech and Pharmaceutical | Tagged ARDS, Aviva Lev-Ari, Inhaled Nitric Oxide, nitric oxide, prostacyclin, Pulmonary hypertension, Respiratory failure
#7
6,839
Author:
AvivaLPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management
#8
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)6,658
Author:
TildaAdvanced Drug Manufacturing Technology, Bio Instrumentation in Experimental Life Sciences Research, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, BioSimilars, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Prevention: Research & Programs, Cell Biology, Signaling & Cell Circuits, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Health Economics and Outcomes Research, Medical Devices R&D Investment, Nanotechnology for Drug Delivery, Pharmaceutical R&D Investment, Population Health Management, Genetics & Pharmaceutical, Regulated Clinical Trials: Design, Methods, Components and IRB related issues, Technology Transfer: Biotech and Pharmaceutical | Tagged Blood test, carbon nanotubes, early detection, Mesothelin, Pancreatic cancer
#9
5,644
Author:
LarryAortic Valve: TAVR, TAVI vs Open Heart Surgery, Biomarkers & Medical Diagnostics, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Coagulation Therapy and Internal Bleeding, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Metabolomics, Mitral Valve: Repair and Replacement, Nitric Oxide in Health and Disease, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Industry Competitive Intelligence, Pharmacotherapy of Cardiovascular Disease, Population Health Management, Nutrition and Phytochemistry, Proteomics | Tagged anti-inflammatory, anti-TNF, Anticoagulant, Antithrombin, blood flow resistance, cell junctions, cellular adhesion, Coumadin, Endothelial cells, Factor IX and IXa, Factor VII and VIIa, Factor VIII and Factor VIIIa, Factor X and Xa, fibrinogen, fibrinolysis, heparin, Hypoxia-inducible factors, Non-steroidal anti-inflammatory drug, Partial thromboplastin time, Physiology, plasmin, platelet aggregation, platelets, prothrombin, soluble fibrin, subendothelial matrix, Thrombin, thrombomodulin, Thrombus, tissue factor, TNF-a, Von Willebrand factor, WH Seegers
#10
Interaction of enzymes and hormones
6,277
Author:
SahaCell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Metabolomics, Population Health Management, Genetics & Pharmaceutical, Population Health Management, Nutrition and Phytochemistry, Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics | Tagged active compounds, enzyme, hormone, interaction, Metabolism, Therapy
#11
Akt inhibition for cancer treatment, where do we stand today?
4,959
Author:
Ziv RavivCANCER BIOLOGY & Innovations in Cancer Therapy, Cell Biology, Signaling & Cell Circuits | Tagged Cancer research, cancer therapy, Cell Biology, mTOR, NF-κB, PI3K/AKT pathway, PTEN, Signal transduction
#12
The History and Creators of Total Parenteral Nutrition
6,294
Author:
Larry
Disease Biology, Gastroenterology Tagged Amino acids, enteral nutrition, Nutrition, TPN
Leave a Reply